| Gene symbol | RHO | Synonyms | CSNBAD1, OPN2, RP4 | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3q22.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | rhodopsin | ||||
| GTO ID | GTC2206 |
| Trial ID | NCT04123626 |
| Disease | Retinitis Pigmentosa |
| Altered gene | RHO |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | QR-1123 |
| Phase | Phase1|Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene |
| Year | 2019 |
| Country | United States |
| Company sponsor | ProQR Therapeutics |
| Other ID(s) | PQ-1123-001 |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||